跳到正文
原文
Medical Xpress·· 3 天前AI 评分50

MD Anderson研究:IL-18作为胰腺癌免疫驱动因子,提示联合KRAS抑制剂治疗潜力

Key immune driver of pancreatic cancer points to combination treatment for slowing progression

AI 导读

德州大学MD安德森癌症中心研究团队在Gastroenterology期刊发表的研究发现,IL-18炎症蛋白促进胰腺癌细胞生长并帮助其逃避免疫清除。在基因工程胰腺癌模型中降低IL-18水平可延缓疾病进展、延长生存,并通过下调CD47表达增强巨噬细胞对肿瘤的杀伤作用。

正文
Scientists identify key immune driver of pancreatic cancer, suggest combination treatment to slow progression
Interleukin-18 (yellow) is robustly expressed in pancreatic cancer cells (magenta, KRT8 staining) and contributes to tumor progression. Credit: Yang Chen, Ph.D.; The University of Texas MD Anderson Cancer Center

Researchers from The University of Texas MD Anderson Cancer Center have discovered that the IL-18 inflammatory protein helps pancreatic tumors grow and evade the immune system, highlighting its potential as a therapeutic target for pancreatic cancer.

Reducing levels of IL-18 in preclinical models reshaped the tumor microenvironment, slowed tumor growth, improved survival and enhanced the effects of KRAS-targeted therapies.

The study, published in Gastroenterology, was co-led by Yang Chen, Ph.D., assistant professor of Translational Molecular Pathology, and Xinlei Sun, Ph.D., postdoctoral fellow in Translational Molecular Pathology.

"Our results show that IL-18 helps pancreatic tumors stay hidden from the immune system and significantly contributes to disease progression and reduced survival," Chen said. "Finding a way to safely target IL-18 in humans could have tremendous potential for enhancing the benefits of KRAS-targeted therapies and improving patient outcomes."

What is IL-18 and why does it matter in pancreatic cancer?

IL-18 is a pro-inflammatory protein that helps regulate the immune response. It is known to be elevated in pancreatic cancer and is typically associated with poor patient outcomes. To understand its role, the researchers created genetically engineered models of pancreatic cancer with reduced IL-18 protein levels and examined the resulting tumor microenvironment. Reducing IL-18 delayed disease progression and extended survival in these models.

Further single-cell analyses revealed that IL-18 increases levels of CD47, a protein that is known as the "don't eat me" signal because it helps cancer cells avoid being cleared by macrophage immune cells. Without IL-18, macrophages were better able to identify and destroy tumor cells. These results suggest that IL-18 somehow influences macrophage recruitment, retention or survival within the tumor microenvironment.

How does IL-18 affect KRAS-targeted treatments?

KRAS inhibitors are promising therapies for pancreatic cancer, but some patients can develop treatment resistance. The researchers found that KRAS inhibition increased IL-18 levels, which appears to help tumors survive treatment.

Interestingly, adding KRAS inhibition to preclinical models without IL-18 improved the antitumor response. These findings suggest that targeting IL-18 may enhance macrophage response and may improve responses to KRAS inhibitor therapies in patients with pancreatic cancer.

What's next for this research?

These results are preclinical, and further studies are needed to develop and test IL-18-targeted therapies to determine how best to safely combine them with KRAS inhibitors or other treatment approaches.

Publication details

Xinlei Sun et al., Depletion of Endogenous IL-18 Suppresses Pancreatic Cancer Progression, Reprograms the Tumor Microenvironment, and Enhances KRAS Inhibitor Efficacy, Gastroenterology (2026). DOI: 10.1053/j.gastro.2026.10.383

Journal information: Gastroenterology

Who's behind this story?

Sadie Harley

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Key immune driver of pancreatic cancer points to combination treatment for slowing progression (2026, November 17) retrieved 17 November 2026 from https://medicalxpress.com/news/2026-11-key-immune-driver-pancreatic-cancer.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com